Skip to main content
Erschienen in: Digestive Diseases and Sciences 8/2022

28.09.2021 | Original Article

Loss to Follow-Up and Health Care Utilization After Initial Diagnosis of Eosinophilic Esophagitis

verfasst von: Nicole C. Chang, Corey J. Ketchem, Swathi Eluri, Manaswita Tappata, Kisan Thakkar, S. Ryanne Corder, Jared A. Sninsky, Craig C. Reed, Evan S. Dellon

Erschienen in: Digestive Diseases and Sciences | Ausgabe 8/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

Eosinophilic esophagitis (EoE) is a chronic disease, but the extent of patient loss to follow-up (LTFU) and health care utilization has not been fully investigated.

Aim

To determine frequency and predictors of LTFU and health care utilization in EoE patients.

Methods

In this retrospective cohort study, we extracted data from patients with a new diagnosis of EoE. Follow-up time for each patient was calculated as the time from the first diagnostic endoscopy to the last GI-related contact date in the medical record. Patients with and without LTFU were compared, and the volume of EoE-related health care interactions was recorded.

Results

Of 944 EoE cases, 249 (26%) met the definition for LTFU. Major reasons for LTFU were never being scheduled (45%) and inability to contact patients (40%). Factors independently associated with regular follow-up were having insurance (aOR 2.89; 95% CI 1.85–4.50), white race (aOR 2.16; 95% CI 1.37–3.41), and longer symptom length (aOR 1.04 per year; 95% CI 1.01–1.08). At the time of last contact, patients with follow-up had better symptom response (55% vs. 12%; p < 0.001), improved esophageal caliber (14.3 vs. 12.4 mm; p = 0.005), and more histologic response (45% vs. 4% at 15 eos/hpf; p < 0.001). Health care utilization was high, with an average of 4.6 endoscopies and 4.0 clinic visits over the follow-up period.

Conclusions

LTFU of newly diagnosed EoE cases was common and associated with lack of insurance, non-white race, and shorter symptom duration. Those who followed up had high health care utilization but improved response rates. Strategies are needed to help decrease LTFU in EoE.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat O’Shea KM, Aceves SS, Dellon ES et al. Pathophysiology of eosinophilic esophagitis. Gastroenterology 2018;154:333–345.CrossRef O’Shea KM, Aceves SS, Dellon ES et al. Pathophysiology of eosinophilic esophagitis. Gastroenterology 2018;154:333–345.CrossRef
2.
Zurück zum Zitat Dellon ES, Hirano I. Epidemiology and natural history of eosinophilic esophagitis. Gastroenterology 2018;154:319–332. CrossRef Dellon ES, Hirano I. Epidemiology and natural history of eosinophilic esophagitis. Gastroenterology 2018;154:319–332. CrossRef
3.
Zurück zum Zitat Liacouras CA, Furuta GT, Hirano I et al. Eosinophilic esophagitis: Updated consensus recommendations for children and adults. J Allergy Clin Immunol 2011;128:3–20.CrossRef Liacouras CA, Furuta GT, Hirano I et al. Eosinophilic esophagitis: Updated consensus recommendations for children and adults. J Allergy Clin Immunol 2011;128:3–20.CrossRef
4.
Zurück zum Zitat Hirano I, Chan ES, Rank MA et al. AGA Institute and the joint task force on allergy-immunology practice parameters clinical guidelines for the management of eosinophilic esophagitis. Gastroenterology. 2020;158:1776–1786.CrossRef Hirano I, Chan ES, Rank MA et al. AGA Institute and the joint task force on allergy-immunology practice parameters clinical guidelines for the management of eosinophilic esophagitis. Gastroenterology. 2020;158:1776–1786.CrossRef
5.
Zurück zum Zitat Rank MA, Sharaf RN, Furuta GT et al. Technical review on the management of eosinophilic esophagitis: A report from the AGA Institute and the joint task force on allergy-immunology practice parameters. Gastroenterology. 2020;158:1789–1810.CrossRef Rank MA, Sharaf RN, Furuta GT et al. Technical review on the management of eosinophilic esophagitis: A report from the AGA Institute and the joint task force on allergy-immunology practice parameters. Gastroenterology. 2020;158:1789–1810.CrossRef
6.
Zurück zum Zitat Philpott H, Dellon ES. The role of maintenance therapy in eosinophilic esophagitis: Who, why, and how? J Gastroenterol. 2018;53:165–171.CrossRef Philpott H, Dellon ES. The role of maintenance therapy in eosinophilic esophagitis: Who, why, and how? J Gastroenterol. 2018;53:165–171.CrossRef
7.
Zurück zum Zitat Dellon ES, Gupta SK. A conceptual approach to understanding treatment response in eosinophilic esophagitis. Clin Gastroenterol Hepatol 2019;17:2149–2160.CrossRef Dellon ES, Gupta SK. A conceptual approach to understanding treatment response in eosinophilic esophagitis. Clin Gastroenterol Hepatol 2019;17:2149–2160.CrossRef
8.
Zurück zum Zitat Chehade M, Kamboj AP, Atkins D, Gehman LT. Diagnostic delay in patients with eosinophilic gastritis and/or duodenitis: A population-based study. J Allergy Clin Immunol Pract. 2021;9:2050–2059.CrossRef Chehade M, Kamboj AP, Atkins D, Gehman LT. Diagnostic delay in patients with eosinophilic gastritis and/or duodenitis: A population-based study. J Allergy Clin Immunol Pract. 2021;9:2050–2059.CrossRef
9.
Zurück zum Zitat Reed CC, Koutlas NT, Robey BS, Hansen J, Dellon ES. Prolonged time to diagnosis of eosinophilic esophagitis despite increasing knowledge of the disease. Clin Gastroenterol Hepatol. 2018;16:1667–1669.CrossRef Reed CC, Koutlas NT, Robey BS, Hansen J, Dellon ES. Prolonged time to diagnosis of eosinophilic esophagitis despite increasing knowledge of the disease. Clin Gastroenterol Hepatol. 2018;16:1667–1669.CrossRef
10.
Zurück zum Zitat Chehade M. Eosinophilic gastrointestinal disorders: The journey to diagnosis remains arduous. Ann Allergy Asthma Immunol. 2020;124:229–230.CrossRef Chehade M. Eosinophilic gastrointestinal disorders: The journey to diagnosis remains arduous. Ann Allergy Asthma Immunol. 2020;124:229–230.CrossRef
11.
Zurück zum Zitat Dellon ES. Cost-effective care in eosinophilic esophagitis. Ann Allergy Asthma Immunol 2019;123:166–172.CrossRef Dellon ES. Cost-effective care in eosinophilic esophagitis. Ann Allergy Asthma Immunol 2019;123:166–172.CrossRef
13.
Zurück zum Zitat Dellon ES, Liacouras CA, Molina-Infante J et al. Updated international consensus diagnostic criteria for eosinophilic esophagitis: Proceedings of the AGREE conference. Gastroenterology 2018;155:1022–1033.CrossRef Dellon ES, Liacouras CA, Molina-Infante J et al. Updated international consensus diagnostic criteria for eosinophilic esophagitis: Proceedings of the AGREE conference. Gastroenterology 2018;155:1022–1033.CrossRef
14.
Zurück zum Zitat Furuta GT, Liacouras CA, Collins MH et al. Eosinophilic esophagitis in children and adults: A systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology. 2007;133:1342–1363.CrossRef Furuta GT, Liacouras CA, Collins MH et al. Eosinophilic esophagitis in children and adults: A systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology. 2007;133:1342–1363.CrossRef
15.
Zurück zum Zitat Dellon ES, Gonsalves N, Hirano I, Furuta GT, Liacouras CA, Katzka DA. ACG clinical guideline: Evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). Am J Gastroenterol. 2013;108:679–692.CrossRef Dellon ES, Gonsalves N, Hirano I, Furuta GT, Liacouras CA, Katzka DA. ACG clinical guideline: Evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). Am J Gastroenterol. 2013;108:679–692.CrossRef
16.
Zurück zum Zitat Reed CC, Corder SR, Kim E et al. Psychiatric comorbidities and psychiatric medication use are highly prevalent in patients with eosinophilic esophagitis and associate with clinical presentation. Am J Gastroenterol. 2020;115:853.CrossRef Reed CC, Corder SR, Kim E et al. Psychiatric comorbidities and psychiatric medication use are highly prevalent in patients with eosinophilic esophagitis and associate with clinical presentation. Am J Gastroenterol. 2020;115:853.CrossRef
17.
Zurück zum Zitat Reed CC, Fan C, Koutlas NT, Shaheen NJ, Dellon ES. Food elimination diets are effective for long-term treatment of adults with eosinophilic oesophagitis. Aliment Pharmacol Ther. 2017;46:836–844.CrossRef Reed CC, Fan C, Koutlas NT, Shaheen NJ, Dellon ES. Food elimination diets are effective for long-term treatment of adults with eosinophilic oesophagitis. Aliment Pharmacol Ther. 2017;46:836–844.CrossRef
18.
Zurück zum Zitat Runge TM, Eluri S, Cotton CC et al. Outcomes of esophageal dilation in eosinophilic esophagitis: Safety, efficacy, and persistence of the fibrostenotic phenotype. Am J Gastroenterol. 2016;111:206.CrossRef Runge TM, Eluri S, Cotton CC et al. Outcomes of esophageal dilation in eosinophilic esophagitis: Safety, efficacy, and persistence of the fibrostenotic phenotype. Am J Gastroenterol. 2016;111:206.CrossRef
19.
Zurück zum Zitat Eluri S, Runge TM, Hansen J, et al. Diminishing effectiveness of long-term maintenance topical steroid therapy in PPI non-responsive eosinophilic esophagitis. Clin Transl Gastroenterol. 2017;8:e97. Eluri S, Runge TM, Hansen J, et al. Diminishing effectiveness of long-term maintenance topical steroid therapy in PPI non-responsive eosinophilic esophagitis. Clin Transl Gastroenterol. 2017;8:e97.
21.
Zurück zum Zitat Wolf WA, Cotton CC, Green DJ et al. Evaluation of histologic cutpoints for treatment response in eosinophilic esophagitis. J Gastroenterol Hepatol Res. 2015;4:1780.CrossRef Wolf WA, Cotton CC, Green DJ et al. Evaluation of histologic cutpoints for treatment response in eosinophilic esophagitis. J Gastroenterol Hepatol Res. 2015;4:1780.CrossRef
22.
Zurück zum Zitat Reed CC, Wolf WA, Cotton CC et al. Optimal histologic cutpoints for treatment response in patients with eosinophilic esophagitis: Analysis of data from a prospective cohort study. Clin Gastroenterol Hepatol. 2018;16:226–233.CrossRef Reed CC, Wolf WA, Cotton CC et al. Optimal histologic cutpoints for treatment response in patients with eosinophilic esophagitis: Analysis of data from a prospective cohort study. Clin Gastroenterol Hepatol. 2018;16:226–233.CrossRef
23.
Zurück zum Zitat Hirano I, Moy N, Heckman MG, Thomas CS, Gonsalves N, Achem SR. Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: Validation of a novel classification and grading system. Gut. 2013;62:489–495.CrossRef Hirano I, Moy N, Heckman MG, Thomas CS, Gonsalves N, Achem SR. Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: Validation of a novel classification and grading system. Gut. 2013;62:489–495.CrossRef
24.
Zurück zum Zitat Dellon ES, Cotton CC, Gebhart JH et al. Accuracy of the eosinophilic esophagitis endoscopic reference score in diagnosis and determining response to treatment. Clin Gastroenterol Hepatol. 2016;14:31–39.CrossRef Dellon ES, Cotton CC, Gebhart JH et al. Accuracy of the eosinophilic esophagitis endoscopic reference score in diagnosis and determining response to treatment. Clin Gastroenterol Hepatol. 2016;14:31–39.CrossRef
25.
Zurück zum Zitat Wolf WA, Cotton CC, Green DJ et al. Predictors of response to steroid therapy for eosinophilic esophagitis and treatment of steroid-refractory patients. Clin Gastroenterol Hepatol. 2015;13:452–458.CrossRef Wolf WA, Cotton CC, Green DJ et al. Predictors of response to steroid therapy for eosinophilic esophagitis and treatment of steroid-refractory patients. Clin Gastroenterol Hepatol. 2015;13:452–458.CrossRef
26.
Zurück zum Zitat Schoepfer AM, Panczak R, Zwahlen M et al. How do gastroenterologists assess overall activity of eosinophilic esophagitis in adult patients? Am J Gastroenterol. 2015;110:402–414.CrossRef Schoepfer AM, Panczak R, Zwahlen M et al. How do gastroenterologists assess overall activity of eosinophilic esophagitis in adult patients? Am J Gastroenterol. 2015;110:402–414.CrossRef
27.
Zurück zum Zitat Kovačić M, Unić J, Mišak Z et al. One-year outcomes in children with eosinophilic esophagitis. Esophagus. 2019;16:162–167.CrossRef Kovačić M, Unić J, Mišak Z et al. One-year outcomes in children with eosinophilic esophagitis. Esophagus. 2019;16:162–167.CrossRef
28.
Zurück zum Zitat Safroneeva E, Straumann A, Coslovsky M et al. Symptoms have modest accuracy in detecting endoscopic and histologic remission in adults with eosinophilic esophagitis. Gastroenterology. 2016;150:581–590.CrossRef Safroneeva E, Straumann A, Coslovsky M et al. Symptoms have modest accuracy in detecting endoscopic and histologic remission in adults with eosinophilic esophagitis. Gastroenterology. 2016;150:581–590.CrossRef
29.
Zurück zum Zitat Kuchen T, Straumann A, Safroneeva E et al. Swallowed topical corticosteroids reduce the risk for long-lasting bolus impactions in eosinophilic esophagitis. Allergy Eur J Allergy Clin Immunol. 2014;69:1248–1254.CrossRef Kuchen T, Straumann A, Safroneeva E et al. Swallowed topical corticosteroids reduce the risk for long-lasting bolus impactions in eosinophilic esophagitis. Allergy Eur J Allergy Clin Immunol. 2014;69:1248–1254.CrossRef
30.
Zurück zum Zitat Straumann A, Spichtin HP, Grize L, Bucher KA, Beglinger C, Simon HU. Natural history of primary eosinophilic esophagitis: A follow-up of 30 adult patients for up to 11.5 years. Gastroenterology. 2003;125:1660–1669. Straumann A, Spichtin HP, Grize L, Bucher KA, Beglinger C, Simon HU. Natural history of primary eosinophilic esophagitis: A follow-up of 30 adult patients for up to 11.5 years. Gastroenterology. 2003;125:1660–1669.
31.
Zurück zum Zitat Dellon ES, Woosley JT, Arrington A et al. Rapid recurrence of eosinophilic esophagitis activity after successful treatment in the observation phase of a randomized, double-blind, double-dummy trial. Clin Gastroenterol Hepatol. 2020;18:1483-1492.e2.CrossRef Dellon ES, Woosley JT, Arrington A et al. Rapid recurrence of eosinophilic esophagitis activity after successful treatment in the observation phase of a randomized, double-blind, double-dummy trial. Clin Gastroenterol Hepatol. 2020;18:1483-1492.e2.CrossRef
32.
Zurück zum Zitat Straumann A, Lucendo AJ, Miehlke S et al. Budesonide orodispersible tablets maintain remission in a randomized, placebo-controlled trial of patients with eosinophilic esophagitis. Gastroenterology. 2020;159:1672–1685.CrossRef Straumann A, Lucendo AJ, Miehlke S et al. Budesonide orodispersible tablets maintain remission in a randomized, placebo-controlled trial of patients with eosinophilic esophagitis. Gastroenterology. 2020;159:1672–1685.CrossRef
33.
Zurück zum Zitat Straumann A, Conus S, Degen L et al. Long-term budesonide maintenance treatment is partially effective for patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2011;9:400-409.e1.CrossRef Straumann A, Conus S, Degen L et al. Long-term budesonide maintenance treatment is partially effective for patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2011;9:400-409.e1.CrossRef
34.
Zurück zum Zitat Mukkada V, Falk GW, Eichinger CS, King D, Todorova L, Shaheen NJ. Health-related quality of life and costs associated with eosinophilic esophagitis: A systematic review. Clin Gastroenterol Hepatol. 2018;16:495–503.CrossRef Mukkada V, Falk GW, Eichinger CS, King D, Todorova L, Shaheen NJ. Health-related quality of life and costs associated with eosinophilic esophagitis: A systematic review. Clin Gastroenterol Hepatol. 2018;16:495–503.CrossRef
35.
Zurück zum Zitat Jensen ET, Kappelman MD, Martin CF, Dellon ES. Health-care utilization, costs, and the burden of disease related to eosinophilic esophagitis in the United States. Am J Gastroenterol. 2015;110:626.CrossRef Jensen ET, Kappelman MD, Martin CF, Dellon ES. Health-care utilization, costs, and the burden of disease related to eosinophilic esophagitis in the United States. Am J Gastroenterol. 2015;110:626.CrossRef
37.
Zurück zum Zitat Hannan N, Steel A, McMillan SS, Tiralongo E. Health service use and treatment choices for pediatric eosinophilic esophagitis: Findings from a Cross-Sectional Survey of Australian Carers. Front Pediatr. 2020;17:147.CrossRef Hannan N, Steel A, McMillan SS, Tiralongo E. Health service use and treatment choices for pediatric eosinophilic esophagitis: Findings from a Cross-Sectional Survey of Australian Carers. Front Pediatr. 2020;17:147.CrossRef
38.
Zurück zum Zitat Hiremath G, Kodroff E, Strobel MJ et al. Individuals affected by eosinophilic gastrointestinal disorders have complex unmet needs and frequently experience unique barriers to care. Clin Res Hepatol Gastroenterol. 2018;42:483–493.CrossRef Hiremath G, Kodroff E, Strobel MJ et al. Individuals affected by eosinophilic gastrointestinal disorders have complex unmet needs and frequently experience unique barriers to care. Clin Res Hepatol Gastroenterol. 2018;42:483–493.CrossRef
Metadaten
Titel
Loss to Follow-Up and Health Care Utilization After Initial Diagnosis of Eosinophilic Esophagitis
verfasst von
Nicole C. Chang
Corey J. Ketchem
Swathi Eluri
Manaswita Tappata
Kisan Thakkar
S. Ryanne Corder
Jared A. Sninsky
Craig C. Reed
Evan S. Dellon
Publikationsdatum
28.09.2021
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 8/2022
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-021-07259-w

Weitere Artikel der Ausgabe 8/2022

Digestive Diseases and Sciences 8/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.